arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

Replimune Group, Inc.

REPL
$12.96 ▼ -0.48 (-3.61%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
38 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Replimune Group, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -28.4%
FCF / Share $-0.78
Trailing P/E
Price / Book 10.3x
FCF Yield
Debt / Equity 0.80
info Valuation on last close. End-of-day price, Sep 23, 2026.

38-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-69.77M
↑ +19.5%
FCF / Share Free cash flow per share
$-0.78
↑ +7.1%
Long-Term Debt Long-term obligations
$84.11M
↑ +1.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
3
Financial Health
30
Cash Quality
55

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 10 years · 38 quarters